Angelini Ventures: 17 million investment in Medical Microinstrument alongside the EIB

Angelini Ventures, the venture capital arm of Angelini Industries, and the European Investment Bank (EIB) have announced a new co-investment of €17 million in MMI (Medical Microinstrument, Inc.), a medtech company developing robotic solutions for microsurgery and super-microsurgery, founded in Italia in 2015 by Massimiliano Simi, Giuseppe Prisco and Hannah Teichmann. This agreement forms part of the EIB-Angelini Ventures partnership signed last December with the aim of providing €150 million in co-financing for European start-ups in the fields of biotechnology and digital health.

MMI has developed the Symani system, equipped with articulated robotic micro-instruments – among the smallest in the world – which enable procedures to be carried out on structures as small as 0.1 mm; thanks to tremor-reduction and motion-scaling technologies, it improves safety, precision and efficiency in surgical procedures for a variety of clinical conditions – including trauma-related reconstructive surgery, head and neck reconstructive surgery, breast cancer and lymphatic repair. The robotic system, the first of its kind to be approved for marketing in the US by the FDA for reconstructive microsurgery, is manufactured at the Italian laboratory in Pisa.

“This new investment marks a concrete step forward in the initiative launched in partnership with the European Investment Bank to support the growth of Europe’s leading healthcare and medtech start-ups and help strengthen a more competitive healthcare ecosystem, capable of attracting capital, accelerate the development of high-impact technologies and transform research into tangible benefits for patients and healthcare systems,” explains Paolo Di Giorgio, CEO of Angelini Ventures. “ We are continuing our work and are already in the process of finalising two further deals; we expect to reach a total of around 100 million invested or committed by early 2027. We are proud to be able to support and accompany MMI in its growth; the company is a prime example of the quality of innovation emerging from Europe and, in this specific case, from Italia: the excellence of this advanced robotic technology will be capable of redefining the standards of microsurgery and increasingly assisting doctors in their day-to-day practice, ensuring positive outcomes for patients”.

“The co-investment in MMI announced today demonstrates how the collaboration between the EIB and Angelini Ventures is helping to strengthen the financing of European innovation in the health sector,” emphasises Alessandro Izzo, the EIB director responsible for Equity, Growth and Project Finance operations. “ “Supporting innovative start-ups in the medtech and biotech sectors means not only fostering the growth of European technology leaders, but also contributing to the competitiveness, strategic autonomy and resilience of our healthcare systems.”

Under the agreement signed in December 2025, the EIB and Angelini Ventures plan to co-invest €150 million (€75 million each) in 7–10 European start-ups developing innovative solutions that are particularly well-suited to market launch, for example in fields such as biotechnology, medical technology and digital health. This is the first agreement signed by the EIB with a corporate venture capital firm in the healthcare sector.